IPCEI Med4Cure Decision Published at the Commission’s State Aid Register
The Commission has published the decision approving the first Important Project of Common European Interest (IPCEI) in the health sector to support research, innovation and the first industrial deployment of healthcare products, as well as innovative production processes of pharmaceuticals in six Member States.
The project is named ‘IPCEI Med4Cure’, was jointly notified by Belgium, France, Hungary, Italy, Slovakia and Spain and approved the past 28th May 2024.
The IPCEI Med4Cure initiative will drive €5.9 billion in private investments and involve 13 companies, including nine SMEs, across 14 innovative projects. It focuses on research and development along the pharmaceutical value chain, from studying biological samples to developing sustainable production technologies and advanced digital applications.
The project aims to accelerate medical advancements, address unmet medical needs—such as rare diseases—and enhance the EU health sector’s resilience. Additionally, it seeks to improve healthcare quality, strengthen preparedness for health crises, and contribute to the green transition.
The Commission approved the measures under the 2021 Communication on Important Projects of Common European Interest (IPCEI Communication).
For more information, see the text of the decisions in the State aid register: SA.104974 IPCEI Med4Cure – France (coordinating), SA.105126 IPCEI Med4Cure – Hungary, SA.105098 IPCEI Med4Cure – Spain, SA.105097 IPCEI Med4Cure – Slovakia, SA.105088 IPCEI Med4Cure – Belgium, SA.105085 IPCEI Med4Cure – Italy.